{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:18:32Z","timestamp":1779934712529,"version":"3.53.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.phrs.2020.105294","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T02:22:49Z","timestamp":1605579769000},"page":"105294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma"],"prefix":"10.1016","volume":"163","author":[{"given":"Maurizio","family":"Viale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Bertone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Maric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Emionite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Bocchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.phrs.2020.105294_bib0005","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr. Med. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2020.105294_bib0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pcad.2006.10.002","article-title":"Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management","volume":"49","author":"Takemura","year":"2007","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2020.105294_bib0015","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.phrs.2020.105294_bib0020","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000265166","article-title":"Doxorubicin cardiomyopathy","volume":"115","author":"Chatterjee","year":"2010","journal-title":"Cardiology"},{"issue":"6","key":"10.1016\/j.phrs.2020.105294_bib0025","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/153303460800700611","article-title":"Recent advances in protection against doxorubicin-induced toxicity","volume":"7","author":"Injac","year":"2008","journal-title":"Technol. Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.phrs.2020.105294_bib0030","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae-the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.phrs.2020.105294_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.phrs.2020.105294_bib0040","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","article-title":"Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes","volume":"26","author":"Tahover","year":"2015","journal-title":"Anticancer Drugs"},{"issue":"4","key":"10.1016\/j.phrs.2020.105294_bib0045","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/1061186X.2017.1380655","article-title":"Advances in nano-delivery systems for doxorubicin: an updated insight","volume":"26","author":"Kanwal","year":"2018","journal-title":"J. Drug Target."},{"issue":"1 Pt A","key":"10.1016\/j.phrs.2020.105294_bib0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.bbagen.2015.09.012","article-title":"Using solution X-ray scattering to determine the high-resolution structure and morphology of PEGylated liposomal doxorubicin nanodrugs","volume":"1860","author":"Schilt","year":"2016","journal-title":"Biochim. Biophy. Acta"},{"issue":"4","key":"10.1016\/j.phrs.2020.105294_bib0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Sangeeta Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"issue":"24","key":"10.1016\/j.phrs.2020.105294_bib0060","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1002\/cncr.30934","article-title":"Historical time to disease progression and progression-free survival in patients with recurrent\/refractory neuroblastoma treated in the modern era on Children\u2019s Oncology Group early-phase trials","volume":"123","author":"London","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.phrs.2020.105294_bib0065","first-page":"413","article-title":"Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study","volume":"8","author":"Marina","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2020.105294_bib0070","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10637-017-0461-0","article-title":"New doxorubicin nanocarriers based on cyclodextrins","volume":"35","author":"Viale","year":"2017","journal-title":"Invest. New Drugs"},{"issue":"4","key":"10.1016\/j.phrs.2020.105294_bib0075","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.pharep.2018.02.014","article-title":"Characterization of drug release from fibrin gels loaded with different pharmaceutical and experimental doxorubicin formulations","volume":"70","author":"Viale","year":"2018","journal-title":"Pharmacol. Rep."},{"issue":"8","key":"10.1016\/j.phrs.2020.105294_bib0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11095-019-2636-1","article-title":"Fibrin gels entrapment of a poly-cyclodextrin nanocarriers as a doxorubicin delivery system in an orthotopic model of neuroblastoma: evaluation of in vitro activity and in vivo toxicity","volume":"36","author":"Viale","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2020.105294_bib0085","doi-asserted-by":"crossref","first-page":"114811","DOI":"10.1016\/j.taap.2019.114811","article-title":"Fibrin gels entrapment of a doxorubicin-containing targeted polycyclodextrin: evaluation of in vivo anti-tumor activity in orthotopic models of human neuroblastoma","volume":"385","author":"Viale","year":"2019","journal-title":"Tox. Appl. Pharm."},{"issue":"6","key":"10.1016\/j.phrs.2020.105294_bib0090","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s10637-015-0291-x","article-title":"Fibrin gels loaded with cisplatin and cisplatin-hyaluronate complexes tested in a subcutaneous human melanoma model","volume":"33","author":"Viale","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"29","key":"10.1016\/j.phrs.2020.105294_bib0095","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.2174\/092986707782793916","article-title":"Ligand targeted liposomal therapies of neuroblastoma","volume":"14","author":"Pastorino","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105294_bib0100","series-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2004"},{"issue":"12","key":"10.1016\/j.phrs.2020.105294_bib0105","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte","year":"2013","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105294_bib0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00273522","article-title":"Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and anti-tumor efficacy of doxorubicin","volume":"23","author":"Balazsovits","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2020.105294_bib0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cld.2015.01.008","article-title":"Locoregional therapy of hepatocellular carcinoma","volume":"19","author":"Habib","year":"2015","journal-title":"Clin. Liver Dis. (Hoboken)"},{"issue":"6 Suppl 2","key":"10.1016\/j.phrs.2020.105294_bib0120","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1097\/JTO.0b013e3181dcf754","article-title":"Locoregional therapy","volume":"5","author":"Schil","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"23","key":"10.1016\/j.phrs.2020.105294_bib0125","first-page":"6641","article-title":"Locoregional cancer treatment with magnetic drug targeting","volume":"60","author":"Alexiou","year":"2000","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2020.105294_bib0130","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/1120009X.1989.11738916","article-title":"Skin and perivascular toxicity induced experimentally by doxorubicin","volume":"1","author":"Balsari","year":"1989","journal-title":"J. Chemother."},{"issue":"6","key":"10.1016\/j.phrs.2020.105294_bib0135","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/bjc.1985.267","article-title":"Poly-L-aspartic acid as a carrier for doxorubicin: a comparative in vivo study of free and polymer-bound drug","volume":"52","author":"Pratesi","year":"1985","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2020.105294_bib0140","first-page":"290","article-title":"A simple and fast experimental model of myocardial infarction in the mouse","volume":"33","author":"Wang","year":"2006","journal-title":"Tex. Heart Inst. J."},{"issue":"1","key":"10.1016\/j.phrs.2020.105294_bib0145","doi-asserted-by":"crossref","first-page":"e000272","DOI":"10.1136\/openhrt-2015-000272","article-title":"The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment","volume":"2","author":"Weng","year":"2015","journal-title":"Open Heart"},{"issue":"4","key":"10.1016\/j.phrs.2020.105294_bib0150","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s00268-009-0252-7","article-title":"Fibrin sealant: past, present, and future: a brief review","volume":"34","author":"Spotnitz","year":"2010","journal-title":"World J. Surg."},{"issue":"3","key":"10.1016\/j.phrs.2020.105294_bib0155","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/jocs.12099","article-title":"Use of fibrin sealants in cardiovascular surgery: a systematic review","volume":"28","author":"Rousou","year":"2013","journal-title":"J. Card. Surg."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820316029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:21:46Z","timestamp":1760912506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820316029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":31,"alternative-id":["S1043661820316029"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105294","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced therapeutic index of liposomal doxorubicin Myocet locally delivered by fibrin gels in immunodeficient mice bearing human neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105294","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105294"}}